{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,17]],"date-time":"2026-11-17T23:41:45Z","timestamp":1794958905639,"version":"4.9.1"},"reference-count":50,"publisher":"BMJ","issue":"8","funder":[{"DOI":"10.13039\/100000050","name":"National Heart, Lung, and Blood Institute","doi-asserted-by":"publisher","award":["P01HL103455"],"award-info":[{"award-number":["P01HL103455"]}],"id":[{"id":"10.13039\/100000050","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000050","name":"National Heart, Lung, and Blood Institute","doi-asserted-by":"publisher","award":["R01 HL098032"],"award-info":[{"award-number":["R01 HL098032"]}],"id":[{"id":"10.13039\/100000050","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000050","name":"National Heart, Lung, and Blood Institute","doi-asserted-by":"publisher","award":["R01 HL125886-01"],"award-info":[{"award-number":["R01 HL125886-01"]}],"id":[{"id":"10.13039\/100000050","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000050","name":"National Heart, Lung, and Blood Institute","doi-asserted-by":"publisher","award":["R01 HL128304"],"award-info":[{"award-number":["R01 HL128304"]}],"id":[{"id":"10.13039\/100000050","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000050","name":"National Heart, Lung, and Blood Institute","doi-asserted-by":"publisher","award":["R01 HL133864"],"award-info":[{"award-number":["R01 HL133864"]}],"id":[{"id":"10.13039\/100000050","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000050","name":"National Heart, Lung, and Blood Institute","doi-asserted-by":"publisher","award":["R25 HL128640-03"],"award-info":[{"award-number":["R25 HL128640-03"]}],"id":[{"id":"10.13039\/100000050","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000050","name":"National Heart, Lung, and Blood Institute","doi-asserted-by":"publisher","award":["T32 HL007563"],"award-info":[{"award-number":["T32 HL007563"]}],"id":[{"id":"10.13039\/100000050","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Vitalant","id":[{"id":"https:\/\/ror.org\/057kyc739","id-type":"ROR","asserted-by":"crossref"}]},{"DOI":"10.13039\/100000968","name":"American Heart Association","doi-asserted-by":"publisher","award":["Established Investigator Award"],"award-info":[{"award-number":["Established Investigator Award"]}],"id":[{"id":"10.13039\/100000968","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["Heart"],"accepted":{"date-parts":[[2019,11,25]]},"published-print":{"date-parts":[[2020,4]]},"abstract":"<jats:p>Sickle cell disease (SCD) is caused by a single point mutation in the gene that codes for beta globin synthesis, causing haemoglobin polymerisation, red blood cell stiffening and haemolysis under low oxygen and pH conditions. Downstream effects include widespread vasculopathy due to recurring vaso-occlusive events and haemolytic anaemia, affecting all organ systems. Cardiopulmonary complications are the leading cause of death in patients with SCD, primarily resulting from diastolic heart failure (HF) and\/or pulmonary hypertension (PH). HF in SCD often features biventricular cardiac hypertrophy and left ventricular (LV) diastolic dysfunction. Among HF cases in the general population, approximately half occur with preserved ejection fraction (HFpEF). The insidious evolution of HFpEF differs from the relatively acute evolution of HF with reduced ejection fraction. The PH of SCD has diverse origins, which can be pulmonary arterial (precapillary), pulmonary venous (postcapillary) or pulmonary thromboembolic. It is also appreciated that patients with SCD can develop both precapillary and postcapillary PH, with elevations in LV diastolic pressures, as well as elevations in transpulmonary pressure gradient and pulmonary vascular resistance. Regardless of the cause of PH in SCD, its presence significantly reduces functional capacity and increases mortality. PH that occurs in the presence of HFpEF is usually of postcapillary origin. This review aims to assemble what has been learnt from clinical and animal studies about the manifestation of PH-HFpEF in SCD, specifically the contributions of LV diastolic dysfunction and myocardial fibrosis, in an attempt to gain an understanding of its evolution.<\/jats:p>","DOI":"10.1136\/heartjnl-2019-314810","type":"journal-article","created":{"date-parts":[[2019,12,10]],"date-time":"2019-12-10T17:25:13Z","timestamp":1575998713000},"page":"562-568","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":43,"title":["Sickle cell disease: at the crossroads of pulmonary hypertension and diastolic heart failure"],"prefix":"10.1136","volume":"106","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9226-0077","authenticated-orcid":false,"given":"Katherine C","family":"Wood","sequence":"first","affiliation":[{"name":"Pittsburgh Heart, Lung, Blood and Vascular Medicine Institute in the Department of Medicine, University of Pittsburgh, Pittsburgh, Pennsylvania, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark T","family":"Gladwin","sequence":"additional","affiliation":[{"name":"Division of Pulmonary, Allergy and Critical Care Medicine in the Department of Medicine, University of Pittsburgh, Pittsburgh, Pennsylvania, USA"},{"name":"Department of Medicine, University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adam C","family":"Straub","sequence":"additional","affiliation":[{"name":"Division of Pulmonary, Allergy and Critical Care Medicine in the Department of Medicine, University of Pittsburgh, Pittsburgh, Pennsylvania, USA"},{"name":"Department of Pharmacology and Chemical Biology, University of Pittsburgh, Pittsburgh, Pennsylvania, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2019,12,10]]},"reference":[{"key":"2025092006345406000_106.8.562.1","doi-asserted-by":"publisher","DOI":"10.1016\/j.hfc.2014.04.003"},{"key":"2025092006345406000_106.8.562.2","doi-asserted-by":"crossref","first-page":"2780","DOI":"10.1093\/eurheartj\/ehy301","article-title":"Solomon SD and van Veldhuisen DJ. heart failure with preserved ejection fraction: from mechanisms to therapies","volume":"39","author":"CSP","year":"2018","journal-title":"Eur Heart J"},{"key":"2025092006345406000_106.8.562.3","doi-asserted-by":"publisher","DOI":"10.1161\/CIR.0000000000000152"},{"key":"2025092006345406000_106.8.562.4","doi-asserted-by":"publisher","DOI":"10.1007\/s11897-013-0155-7"},{"key":"2025092006345406000_106.8.562.5","doi-asserted-by":"publisher","DOI":"10.1016\/j.pcad.2016.06.002"},{"key":"2025092006345406000_106.8.562.6","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1016\/j.tcm.2018.08.005","article-title":"Pulmonary vascular disease in the setting of heart failure with preserved ejection fraction","volume":"29","author":"Levine","year":"2019","journal-title":"Trends Cardiovasc Med"},{"key":"2025092006345406000_106.8.562.7","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(16)00647-4"},{"key":"2025092006345406000_106.8.562.8","doi-asserted-by":"crossref","first-page":"1143","DOI":"10.1113\/JP275858","article-title":"Insights into the pulmonary vascular complications of heart failure with preserved ejection fraction","volume":"597","author":"Lai","year":"2019","journal-title":"J Physiol"},{"key":"2025092006345406000_106.8.562.9","unstructured":"CDC . Data & Statistics on Sickle Cell Disease 2019."},{"key":"2025092006345406000_106.8.562.10","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1146\/annurev-pathmechdis-012418-012838","article-title":"Pathophysiology of sickle cell disease","volume":"14","author":"Sundd","year":"2019","journal-title":"Annu Rev Pathol"},{"key":"2025092006345406000_106.8.562.11","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2011.10.900"},{"key":"2025092006345406000_106.8.562.12","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2008.598"},{"key":"2025092006345406000_106.8.562.13","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2018.01.017"},{"key":"2025092006345406000_106.8.562.14","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1600311113"},{"key":"2025092006345406000_106.8.562.15","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2017-02-767624"},{"key":"2025092006345406000_106.8.562.16","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.201207-1222OC"},{"key":"2025092006345406000_106.8.562.17","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1005565"},{"key":"2025092006345406000_106.8.562.18","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1016\/S2213-2600(17)30498-8","article-title":"Redefining pulmonary hypertension","volume":"6","author":"Maron","year":"2018","journal-title":"Lancet Respir Med"},{"key":"2025092006345406000_106.8.562.19","doi-asserted-by":"crossref","unstructured":"Simonneau G , Montani D , Celermajer DS , et al . Haemodynamic definitions and updated clinical classification of pulmonary hypertension. Eur Respir J 2019;53.doi:10.1183\/13993003.01913-2018","DOI":"10.1183\/13993003.01913-2018"},{"key":"2025092006345406000_106.8.562.20","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.13812"},{"key":"2025092006345406000_106.8.562.21","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2010-09-306167"},{"key":"2025092006345406000_106.8.562.22","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra0804411"},{"key":"2025092006345406000_106.8.562.23","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2012.068965"},{"key":"2025092006345406000_106.8.562.24","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.111.032920"},{"key":"2025092006345406000_106.8.562.25","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.201401-0065ST"},{"key":"2025092006345406000_106.8.562.26","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.21058"},{"key":"2025092006345406000_106.8.562.27","doi-asserted-by":"publisher","DOI":"10.1159\/000323464"},{"key":"2025092006345406000_106.8.562.28","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.13447"},{"key":"2025092006345406000_106.8.562.29","doi-asserted-by":"publisher","DOI":"10.1097\/MPH.0000000000000184"},{"key":"2025092006345406000_106.8.562.30","doi-asserted-by":"publisher","DOI":"10.1002\/ppul.20996"},{"key":"2025092006345406000_106.8.562.31","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2010.030767"},{"key":"2025092006345406000_106.8.562.32","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0007956","article-title":"Angiogenic and inflammatory markers of cardiopulmonary changes in children and adolescents with sickle cell disease","volume":"4","author":"Niu","year":"2009","journal-title":"PLoS One"},{"key":"2025092006345406000_106.8.562.33","doi-asserted-by":"publisher","DOI":"10.1161\/01.CIR.0000155257.33485.6D"},{"key":"2025092006345406000_106.8.562.34","doi-asserted-by":"publisher","DOI":"10.1159\/000102588"},{"key":"2025092006345406000_106.8.562.35","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcmg.2015.05.013"},{"key":"2025092006345406000_106.8.562.36","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehv555"},{"key":"2025092006345406000_106.8.562.37","doi-asserted-by":"crossref","first-page":"664","DOI":"10.1111\/bjh.15238","article-title":"Cardiac manifestations in sickle cell disease varies with patient genotype","volume":"181","author":"Guedeney","year":"2018","journal-title":"Br J Haematol"},{"key":"2025092006345406000_106.8.562.38","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1016\/j.bcmd.2017.08.005","article-title":"Applications of cardiac magnetic resonance imaging in sickle cell disease","volume":"67","author":"Niss","year":"2017","journal-title":"Blood Cells Mol Dis"},{"key":"2025092006345406000_106.8.562.39","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.114.013215"},{"key":"2025092006345406000_106.8.562.40","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1080\/14779072.2018.1497485","article-title":"Mechanisms, diagnosis, and treatment of heart failure with preserved ejection fraction and diastolic dysfunction","volume":"16","author":"Plitt","year":"2018","journal-title":"Expert Rev Cardiovasc Ther"},{"key":"2025092006345406000_106.8.562.41","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCRESAHA.115.306565"},{"key":"2025092006345406000_106.8.562.42","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbi.2008.05.010"},{"key":"2025092006345406000_106.8.562.43","doi-asserted-by":"crossref","first-page":"636","DOI":"10.1165\/rcmb.2017-0292OC","article-title":"Nitric oxide-independent soluble guanylate cyclase activation improves vascular function and cardiac remodeling in sickle cell disease","volume":"58","author":"Potoka","year":"2018","journal-title":"Am J Respir Cell Mol Biol"},{"key":"2025092006345406000_106.8.562.44","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1165\/rcmb.2016-0166OC","article-title":"Peroxisome proliferator-activated receptor \u03b3 regulates the v-ets avian erythroblastosis virus E26 oncogene homolog 1\/microRNA-27a axis to reduce endothelin-1 and endothelial dysfunction in the sickle cell mouse lung","volume":"56","author":"Kang","year":"2017","journal-title":"Am J Respir Cell Mol Biol"},{"key":"2025092006345406000_106.8.562.45","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2006-08-039438"},{"key":"2025092006345406000_106.8.562.46","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/j.bcmd.2018.10.005","article-title":"Metabolic syndrome among adults living with sickle cell disease","volume":"74","author":"Ogunsile","year":"2019","journal-title":"Blood Cells Mol Dis"},{"key":"2025092006345406000_106.8.562.47","doi-asserted-by":"crossref","first-page":"889","DOI":"10.14740\/jocmr3137w","article-title":"The sixth vital sign: body mass index in patients with sickle cell disease","volume":"9","author":"Ballas","year":"2017","journal-title":"J Clin Med Res"},{"key":"2025092006345406000_106.8.562.48","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1111\/bjh.15773","article-title":"Similar burden of type 2 diabetes among adult patients with sickle cell disease relative to African Americans in the U.S. population: a six-year population-based cohort analysis","volume":"185","author":"Zhou","year":"2019","journal-title":"Br J Haematol"},{"key":"2025092006345406000_106.8.562.49","doi-asserted-by":"publisher","DOI":"10.1016\/j.cardfail.2014.09.001"},{"key":"2025092006345406000_106.8.562.50","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.115.018935"}],"container-title":["Heart"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/heartjnl-2019-314810","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,20]],"date-time":"2025-09-20T13:35:04Z","timestamp":1758375304000},"score":1,"resource":{"primary":{"URL":"https:\/\/heart.bmj.com\/lookup\/doi\/10.1136\/heartjnl-2019-314810"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,12,10]]},"references-count":50,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2020,3,26]]},"published-print":{"date-parts":[[2020,4]]}},"alternative-id":["10.1136\/heartjnl-2019-314810"],"URL":"https:\/\/doi.org\/10.1136\/heartjnl-2019-314810","relation":{},"ISSN":["1355-6037","1468-201X"],"issn-type":[{"value":"1355-6037","type":"print"},{"value":"1468-201X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,12,10]]}}}